CaHA
Hydroxyapatite (CaHA)
A core foundational material for bone repair, aesthetic medicine, scientific research and development, and other high-end application scenarios.
View DetailsNanjing Junzhuo Biotechnology Co., Ltd.Advancing Biomaterials with Precision
Nanjing Junzhuo Biotechnology Co., Ltd. specializes in the R&D, manufacturing, and application support of advanced hydroxyapatite and bioceramic materials. We are committed to delivering highly stable and specialized material solutions for orthopedic reconstruction, medical aesthetic injectables, surface coatings, and translational research.
HydroxyapatiteCaHA Microspheresβ-TCPCalcium SilicateRegenerative Biomaterials
Products
β-TCP
Beta Tricalcium Phosphate (β-TCP)
Beta tricalcium phosphate (β-TCP) is a high-performance bioceramic material with biomimetic mineral characteristics.
View DetailsNEW
New Materials (BCP, CS, CSH)
Centered on material directions such as biphasic calcium phosphate, calcium silicate, and calcium sulfate hemihydrate, we continue to advance the in-depth development of new bioceramic materials.
View DetailsOEM
Custom Development
Across key dimensions such as particle size distribution, morphology, packaging format, and application documentation, we support custom development from requirement communication and sample validation to project onboarding.
View DetailsAbout Junzhuo
Nanjing Junzhuo Biotechnology Co., Ltd. focuses on the research, production, and custom development of high-end biomaterials, providing professional material solutions for customers worldwide.
About Junzhuo
News Center
The latest updates on company developments, technical articles, and industry content.
CaHA Particle Manufacturing: Process Changes and Quality Control
Four 2026 FDA PMA records cover sieving, drying, filtration, and post-sterilization particle-size testing in CaHA manufacturing. They show why release testing, process control, measurement systems, and change control must be read together.
CaHA and Skin Rejuvenation: Gene Expression Is Only the First Layer of Evidence
A 2026 in vitro study compared transcriptional responses to three commercial CaHA formulations in aging-like fibroblasts. mRNA changes do not establish pathway function or skin rejuvenation.
Why Total Collagen Is Not Enough to Evaluate Biostimulatory Materials
A 2026 multiscale study shows that total collagen, type I/III balance, fiber organization, and macrophage state describe different aspects of tissue remodeling.